The new board ultimately ended the annual proxy battles with Icahn by appointing Saunders, the former Bausch & Lomb CEO, as chief executive of Forest Labs in September 2013. Earlier that year, Saunders steered B+L toward acquisition by Valeant Pharmaceuticals for $8.7 billion, only to be relegated to an advisory role for that combined company once their deal was done.